55 results about "Renal epithelial cell" patented technology

Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.

The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

Parathyroid hormone (PTH) and its closely related peptide, PTHrP, share the same receptor, PTHR. LLC-PK1 cells are porcine renal epithelial cells which do not normally express PTHR. The present-invention provides stably transfected LLC-PK1 cells which express human PTHR. Also provided are methods for determining whether a compound of interest is an agonist or antagonist of a Gs or Gq protein coupled receptor.

A method of treating a patient with cardiorenal syndrome and hepatorenal syndrome are provided in which a portion of the body fluid of the patient is exposed to renal epithelial cells, outside of the kidney of the patient, whereby the body fluid is in fluid communication with renal epithelial cells and is modified by renal epithelial cells.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention provides application of oligomeric mannuronic acid to preparation of a medicine for resisting influenza A virus subtype H1N1. Through experiment, the oligomeric mannuronic acid (OM) has a good function of protecting madin-darby canine kidney cells which are infected by influenza A virus subtype H1N1 in vitro, can effectively reduce virus reproduction, and has an effect equal to thatof a positive control medicine ribavirin. Moreover, OM can also reduce the death of mice which is caused by infection of influenza A virus subtype H1N1 obviously, and prolong the survival time. The oligomeric mannuronic acid (OM) has the advantages of high water solubility and stability, and safety and low toxicity and the like; and in an in vivo-in vitro experiment, the OM can resist influenza Avirus subtype H1N1 well, and the oligomeric mannuronic acid can be expected to be developed to the medicine for resisting influenza A virus.

The present invention discloses an artificial substitute unit. It can be implanted into human body and can be used as temporary substitute for retaining specific tissue function. Said substitute includes a peripheral body, a hollow supporting frame placed in said peripheral body interior, intracavity filled cells placed in the inner cavity of said supporting frame and filler and functional cells and nutrient matrix body placed between said supporting frame and peripheral body, on the wall surfaces of the described supporting frame and peripheral body several through microporous channels are uniformly distributed, and the described intracavity filled cells can be induced and differentiated into endothelial tissue cells, and the extracavity filled cells can be changed according to the application direction of artificial substitute unit, and can be induced and differentiated into required functional cells, such as liver cells, pancreatic island beta cells, adrenal cortex cells and fat cells, etc.

The invention relates to a monkey embryo renal epithelial cell Marc-145 suspension adapted strain and an application thereof in the culture of PRRSV (porcine reproductive and respiratory syndrome virus) and production of a PRRSV vaccine, belonging to the field of biotechnology. The monkey embryo renal epithelial cell Marc-145 suspension adapted strain provided by the invention is collected in the China Center for Type Culture Collection, with a collection number CCTCC No:C201542. The invention also discloses a method for culturing PRRSV by use of the Marc-145 cell suspension adapted strain. By adopting the Marc-145 cell suspension adapted strain provided by the invention, full suspension culture of the Marc-145 cell in a culture medium is realized, and thus the PRRSV is produced by use of the Marc-145 cell suspension adapted strain, step-by-step magnification using a bioreactor is easy to realize in industrial production, and large-scale production of PRRSV vaccine is realized; and compared with the existing spinner-bottle and carrier suspension culture technology, the production technology is simplified, the production cycle is shortened, the production cost is reduced, and the quality and yield of PRRSV vaccine are further improved.

The invention relates to a simple and easy dynamic detection method of potassium ion exchange inside and outside a human embryonic kidney epithelial cell (HEK 293) and erythrocyte. The method comprises the following steps of: preparing a nano capillary taking a boron silicon capillary as a material, and carrying out inner wall silanization, thus the nano capillary is changed to be hydrophobic; and filling a 1,2-dichloroethane (DCE) solution containing a K<+> vector in the nano capillary with a hydrophobic inner wall tube, wherein the solution belongs to an organic phase, the HEK293 cell and erythrocyte solution belongs to a water phase, Ag / AgCl belongs to the reference electrode in the water phase, Ag / AgTPBCI is a reference electrode in the organic phase. According to the invention, by utilizing a nano tube ion selective micro electrode, the dynamic detection of K<+> exchange inside and outside the HEK 293 cell and erythrocyte is carried out by cyclic voltammetry, thus the perfect combination of the ion selective electrode and an electrochemical detection technology is realized. The method combines the characteristics of a patch clamp technique and the ion selective electrode, and has the advantages of no destruction, low cost, rapid detection and high sensitivity.

The invention discloses a 22-nor-stigmasta thiosemicarbazone compound and a preparing method and application thereof. The structural formula of the 22-nor-stigmasta thiosemicarbazone compound is shown in the description. In vitro cancer cell growth and proliferation activity inhibition tests show that the prepared 22-nor-stigmasta thiosemicarbazone compound has a remarkable inhibition effect on various tumor cell strains such as human nipple thyroid gland cancer cells, human oral cavity epidermoid carcinoma cells and cervical cancer. Meanwhile, the 22-nor-stigmasta thiosemicarbazone compound is free of cytotoxicity on human kidney epithelial cells (HEK293T) and can be used for preparing medicine for treating cancer.

The invention discloses a monoclonal cell strain. The monoclonal cell strain is a human renal epithelial 293T cell carrying an SIE-regulated luciferase gene and capable of expressing luciferase stably and is named as 293T-SIE (preservation No. CGMCC No. 13816, and the depositary unit is the General Microbiology Center of the China General Microbiological Culture Collection Center); the invention further relates to a construction method and application for the monoclonal cell strain and a method for measuring relative biological activity of IL-6R inhibitors by adopting the monoclonal cell strain. According to the Monoclonal cell strain and application for measuring relative biological activity of the IL-6R inhibitors, the activation situation of IL-6 related signal pathway is taken as a research object, a human renal epithelial cell strain capable of expressing SIE-luciferase reporter gene stably is designed, culturing is simple, repeatability is good, actual action situation of sample in a body is closer, and stability and accuracy of the measuring result are guaranteed; meanwhile, the established method for measuring the activity of the IL-6R inhibitor established is short in measuring period, researching and developing, quality controlling and clinical application of IL-6R inhibitor medicine are facilitated, and high application value is obtained.

The invention discloses a 22-abeo-stigmasterol benzimidazole compound as well as a preparation method and application thereof. The structural formula of the 22-abeo-stigmasterol benzimidazole compound is shown in the specification; experiments for in-vitro inhibition of growth and proliferation activities of cancer cells show that the 22-abeo-stigmasterol benzimidazole compound prepared by the preparation method has remarkable inhibition effect to multiple tumor cell strains such as human papillary thyroid cancer cells, human oral epidermoid carcinoma cells, cancer cell strains of cervical cancer and the like. Meanwhile, the 22-abeo-stigmasterol benzimidazole compound has no cytotoxicity to human kidney epithelial cells (HEK293T) and can be applied to the preparation of drugs for treating cancers.

The invention provides applications of poly mannuronic acid propyl ester sulfate (PMS) in preparing anti- H1N1 influenza A virus medication. Experiments of the invention prove that PMS not only has great inhibition effect on the neuraminidase of the influenza A virus, but also has relatively good protection effect on canine kidney epithelial cells infected with the H1N1 influenza A virus, and can reduce the replication of the H1N1 virus with an effect that equal to the positive control medication ribavirin. Additionally, the PMS can effectively reduce the death rate of mice infected with the H1N1 influenza A virus and the survival time of the mice are prolonged. The poly mannuronic acid propyl ester sulfate provided by the invention has significant activity of inhibiting the neuraminidase of the H1N1 influenza A virus, and is proved to have good anti- H1N1 influenza A virus activity both in vivo and in vitro experiments, which shows the wide application prospect of the poly mannuronic acid propyl ester sulfate in preparing anti-H1N1 influenza A virus medication.

The invention relates to the technical field of biology, in particular to a monoclonal cell strain of human embryonic kidney epithelial cells 293T-Clone3 and application of the monoclonal cell strainof the human embryonic kidney epithelial cells 293T-Clone3. A preservation number of the monoclonal cell strain is CCTCC NO: C2019262, the monoclonal cell strain has high transfection efficiency, thetransfection efficiency is higher than that of commercial AAV293, the transfection efficiency all reaches 90% or above, both the total virogene copy numbers of supernatant and cells of AAV packaged ineach 150-mm vessel are 1011 or above, and can be up to 1012, the virogene copy numbers in supernatant are all 1011 or above, and the virogene copy number of AAV packaged by the AAV293 ranges from 109to 1011. Compared with the AAV293, the monoclonal cell strain of the human embryonic kidney epithelial cells 293T-Clone3 can meet the experiment requirements more.

There is provided a method of differentiating an induced pluripotent stem cell (iPSC) into a renal proximal tubular cell (PTC)-like cell. The method comprises culturing an undifferentiated iPSC in a renal epithelial cell culture medium in the presence of one or more extracellular matrix (ECM) molecules, bone morphogenic protein 2 (BMP2) and bone morphogenic protein 7 (BMP7), for a period of from about 8 to about 10 days, under conditions sufficient to induce differentiation of the iPSC into a PTC-like cell. A cell population of differentiated PTC-like cells is also provided, as well as uses and methods of use of the cell population.

Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.

The invention discloses an in-vitro cell platform for pig gene editing sgRNA screening, and belongs to the field of gene editing. The platform is suitable for sgRNA screening in a CRISPR-Cas9 gene editing technology, and mainly comprises a specific pig cell, a transcriptome of the specific pig cell, a proteome data platform and a gene editing sgRNA screening method. The cell is a pig hip artery endothelial cell PIEC, a pig kidney epithelial cell PK15, a pig kidney passage cell IBRS-2 or a pig testis cell ST capable of stably expressing a Cas9 gene. A user can select specific cells according to the expression level of a gene to be edited in the data platform, and screening of gene editing sgRNA is carried out. According to the in-vitro cell platform, the sgRNA screening efficiency is improved, and the in-vitro cell platform has a good application prospect.

The present invention provides a method to diagnose the kidney function of secreating kidney secreted bone growth factor (KSBGF) by examining the blood concentration of KSBGF, a method to diagnose the state of bone formation by examining the blood concentration of KSBGF, a method to produce KSBGF, a method of using KSBGF to promote bone growth, a method for screening medicine for bone reformation, a method of using flavonol and flavonol glycosides to promote renal epithelial cell proliferation, and the application of flavonol and flavonol glycosides to improve renal function, to treat renal failure, and to promote bone formation.

The invention discloses application of a cyclic erythropoietin-derived peptide in protection of renal injury and cyclosporine A injury. In a control group, the abdominal cavity and renal pedicle are exposed; in IR, two renal pedicles are separated, and are clipped with a vessel clamp for 30 minutes to enable color of the kidneys to be changed, and refilling is performed for 2 or 8 weeks; in IR plus CsA, CsA is dissolved in olive oil, and IR mice are subjected to intragastric administration every day; in IR plus CHBP, CHBP is dissolved in saline water, and the IR mice are subjected to intraperitoneal injection every three days; in IR plus CsA plus CHBP, CsA and CHBP are used for treating the IR mice at the same time; urine albumin / creatinine, serum creatinine, histology, apoptosis, caspase-3 and HMGB1 are evaluated, and intracellular signal channels are screened through a protein chip; and a renal epithelial cell model is established, renal injury is simulated, and the influence of CsA,CHBP and / or caspase-3 siRNA on TCMK1 is studied.

The invention discloses a 2h-pyrazole sulfanilamide steroid saponin aglycone derivative containing indole framework and a preparation method and application thereof. The structure of the 2h-pyrazole sulfanilamide steroid saponin aglycone derivative containing the indole framework is shown as the formula VII in the specification. R1 is selected from H, CH3 and CH2CH3. R2 is selected from H, CH3, CH2CH3, F, C1 and Br. R3 is selected from H and CH3. R4 is selected from H and CH3. The 2h-pyrazole sulfanilamide steroid saponin aglycone derivative has a remarkable restraint effect on breast cancer cells (MCF-7), cervical cancer cells (HeLa), lung cancer cells (A549) and hepatoma cancer cells (HepG2) of human body, has identical or superior cell toxicity to human renal epithelial cells (293T) compared with a positive reference drug (Celecoxib), has better biological cavity, higher selectivity and lower toxicity, and can be used for preparing anti-cancer drugs.

The invention relates to the field of stem cell biology, in particular to a kidney epithelial cell and a preparation method and application thereof. The first disclosed kidney epithelial cell expresses CDH1<+> and PODXL<+>, and at least expresses one of CDH2<+> and LTL<+>. The second disclosed preparation method of the kidney epithelial cell includes the following steps that pluripotent stem cellsare differentiated into posterior streak cells; the posterior streak cells are differentiated into posterior intermediate mesoderms; the posterior intermediate mesoderms are differentiated into kidney progenitor cells; the kidney progenitor cells are differentiated into kidney tubular aggregated precursors; the kidney tubular aggregated precursors are differentiated into kidney vesicles; and thekidney vesicles are differentiated into kidney epithelial cells. The provided preparation method has high differentiation efficiency and stable differentiation effect, and is applied to a variety of hPSC cell lines; and the differentiated nephron progenitor cells can meet the requirements of kidney disease model building, kidney drug toxicity testing, kidney disease related drug screening and other scientific research experiment.

The invention discloses dihydropyrazol piperazine derivatives containing a naphthalene ring skeleton and related preparation method and application in preparation of anti-cancer drugs. The preparation method is characterized by providing the general formula shown in the specification. The dihydropyrazol piperazine derivatives disclosed by the invention have an obvious inhibition effect on human breast cancer cell (MCF-7), cervical cancer cell (HeLa), lung cancer cell (A549) and liver cancer cell (HepG2), and the action effect is approximately equivalent to that of a positive control drug Celecoxib; some of the dihydropyrazol piperazine derivatives containing a naphthalene ring skeleton perform better than the positive control drug; and meanwhile, the derivatives show equivalent or better cytotoxicity to the human renal epithelial cell (293T) than the positive control drug Celecoxib. Therefore, the dihydropyrazol piperazine derivatives containing a naphthalene ring skeleton, disclosed by the invention, have better bioactivity, higher selectivity and lower toxicity.

The invention provides a DNA molecular probe; the molecular probe is DNA molecular probe of miRNA Let-7b; the DNA molecular probe has a stem ring structure. The DNA molecular probe is applied to detect miRNA in the cancer cell, the experimental result shows that miRNA Let-7b has low expression in non-small cell lung cancer, breast cancer cell, and cervical cancer cell, and has high expression in normal human pulmonary epithelial cell, breast cancer epithelial cell and human embryo kidney epithelial cell; the probe can simply and effectively detect the expression level of miRNA in the cancer cell.

The invention provides a triterpenoid compound, a preparation method thereof and application thereof in preparing the anticancer drugs. The triterpenoid compound has a structure represented by the formula (I), R is one of COCH3, COCH2CH3, COAr, One of CH3, CH2CH3, CH2Ar, gamma-D-glucose and gamma-D-galactose, and Ar is a benzene ring. The triterpenoids compound has inhibitory activity against human tumor cells in vitro, the inhibitory effects on tumor cells of the human lung cancer, breast cancer, gastric cancer and the like are more obvious, and the IC50 is lower. The inhibitory effect of thecompound on the tumor cells has a certain broad spectrum in mammals. In addition, the compound has almost no inhibitory activity against 293T of normal human human renal epithelial cells, and it is proved that the compound is less toxic to normal cells and has great medicinal value.

The invention discloses a medicinal composition for preventing or alleviating diabetes and complications of diabetes. The medicinal composition comprises a plant source mixture containing soy isoflavone and an arachidonic acid derivative at the weight ratio being (1:1) to (10:1). Therefore, the medicinal composition for preventing or alleviating diabetes and complications of diabetes can reduce the content of free radicals of the kidney epithelial cells in the in-vitro high-glucose environment, and can promote the insulin concentration, reduce the contents of blood sugar and blood fat, reduce the activity of alanine aminotransferase, reduce inflammatory response and the like in vivo, so that diabetes and complications of diabetes can be prevented or retarded.

Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.